Home Featured Page 275

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

PsyBio and Miami University Broaden Partnership Agreement for the Continued Advancement...

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Mydecine to Report Full Year 2020 Financial Results on May 3,...

Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction...

Red Light Holland and Headland West Indies Lead #SVGStrong, a Relief...

Psychedelic Bulletin: MindMed to List on Nasdaq; Atai IPO Unveiled; Champignon...

PTSF56 – Data vs. Spin, with Tim Cools of Psychedelic Experience

MindMed To Commence Trading on Nasdaq

Champignon Brands Announces Revocation of Cease Trade Orders

Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.